Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Given the renewed focus on mastocytosis (recognized in Italy as a rare disease since 2018) and emerging clinical and immunogenetic knowledge, and considering the rarity of the disease and limited understanding of its progression, this observational study aims to analyze epidemiological, clinical, genetic, immunohistochemical, and laboratory characteristics of patients with mastocytosis. This will help expand knowledge about the disease and identify prognostic variables useful in developing a personalized therapeutic approach.
This registry aims to collect retrospective and prospective data on patients with cutaneous and systemic mastocytosis attending the Dermatology Unit at the IRCCS Fondazione Policlinico San Matteo.
This is a single-center longitudinal hospital registry including patients with cutaneous and systemic mastocytosis, collected retrospectively and prospectively to assess the clinical, serological, hematological, and molecular characteristics of patients with cutaneous and systemic mastocytosis and their correlation with specific outcomes such as disease variant (cutaneous or systemic), extent of skin involvement, and survival rate.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients diagnosed with cutaneous or systemic mastocytosis |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of the systemic disease variant in the examined population | The prevalence and the 95% exact binomial confidence interval will be presented | January 2034 |
| Measure | Description | Time Frame |
|---|---|---|
| Association between clinical, serological, hematological, and molecular characteristics and the disease variant (cutaneous or systemic) | The association will be evaluated using a multivariate logistic model; the number of covariates will be limited by the number of systemic mastocytosis cases, maintaining a 1:10 ratio. The selection of covariates will be made a priori based on scientific knowledge. Odds ratios (OR) and their corresponding 95% confidence intervals (CI) will be reported. The model's discriminatory ability (area under the ROC curve) and its calibration (graphically) will be calculated |
Not provided
Inclusion criteria:
- Cutaneous or systemic mastocytosis diagnosys attending the Dermatology Outpatient Clinics of the UOC Dermatology Unit Fondazione IRCCS Policlinico San Matteo
Not provided
Not provided
Not provided
All patients diagnosed with cutaneous or systemic mastocytosis attending the Dermatology Outpatient Clinics of the UOC Dermatology Unit Fondazione Policlinico San Matteo IRCCS Pavia will be eligible for inclusion in the registry.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Valeria Brazzelli, MD | Contact | 03820503794 | v.brazzelli@smatteo.pv.it |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| SC Dermatologia, Fondazione IRCCS Policlinico San Matteo | Recruiting | Pavia | Pavia | 27100 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D034701 | Mastocytosis, Cutaneous |
| D034721 | Mastocytosis, Systemic |
| ID | Term |
|---|---|
| D008415 | Mastocytosis |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| January 2034 |
| Association between family history and age of disease onset | The analysis will be performed using a multivariate logistic model | January 2034 |
| Survival rate in relation to the disease variant (cutaneous or systemic) | The survival rate will be reported as deaths per 100 person-years; the start date for follow-up will be the diagnosis of the disease. The groups will be compared using the log-rank test, and survival will be described using Kaplan-Meier curves. A Cox model will be used to derive the hazard ratio (HR) and the corresponding 95% confidence interval (CI). Harrell's C-statistic will be calculated to assess the model's discriminatory ability. Estimates will be adjusted, where possible, for potential confounding factors | January 2034 |
| Association between c-KIT mutation in blood and clinical characteristics of the patient | The analysis will be performed using a multivariate logistic model | January 2034 |
| Evaluation of dermatoscopic characteristics in relation to the clinical presentation of the disease and the patient's age | The analysis will be performed using a multivariate logistic model. For the purposes of the analysis, age will be dichotomized at the median. Linear regression models may also be used | January 2034 |
| D009369 | Neoplasms |
| D012878 | Skin Neoplasms |
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D000090362 | Mast Cell Activation Disorders |
| D007154 | Immune System Diseases |